Positive performance continues; AVE Technology welcomes concentrated research by institutional investors

Publication Time:

2024-07-17 00:00

Source:

The company's performance growth trend is obvious, its technological leading advantage continues to be consolidated, and Aiwei Technology (688067), the leader in automated microscopy, has attracted the attention of institutional investors.

On the morning of July 16, Aiwei Technology held a centralized reception event at its company park, with more than 20 representatives from well-known investment institutions such as Hunan Qingyan Venture Capital Management Co., Ltd., Hunan Huazhou Investment Private Equity Fund, Hunan Fuchuan Private Equity Investment Fund, and Founder Securities and Sheng Investment participating in the research.

That day, Aiwei Technology's chairman Ding Jianwen, vice general manager and acting secretary of the board Lin Changqing, chief financial officer Long Kunxiang, and other senior executives introduced the company's recent R&D innovation and high-quality development achievements, and actively interacted with the participating institutional investors, fully demonstrating the style of a sci-tech innovation board company from Hunan province.

Hunan listed company invites an audit firm to participate in investor communication for the first time

It is worth noting that Tianjian Accounting Firm's Hunan branch also participated in the exchange as a co-organizer in this research activity and actively answered investors' questions. It is understood that this is the first time a Hunan listed company has invited an audit firm to participate in a face-to-face investor communication event.

Tianjian Accounting Firm's presence at Aiwei Technology's investor communication event not only helped participating investors further understand the company's finances and internal governance but also represents an important step in the improvement and development of Hunan's capital market.

Industry insiders point out that encouraging audit firms to directly face market investors is beneficial for investors to understand listed companies from multiple dimensions and will also allow audit firms to intuitively feel their 'gatekeeper' responsibilities. It will also promote a 'two-way rush' between Hunan institutions and local companies, helping the company attract more 'patient capital'.

In addition, the China Securities Regulatory Commission recently issued 'Eight Measures to Deepen the Reform of the Sci-Tech Innovation Board and Serve Scientific and Technological Innovation and High-Quality Development' (referred to as 'Eight Measures for Sci-Tech Innovation'), further deepening reforms, improving inclusiveness for new industries, new business models, and new technologies, playing the role of the capital market, and better serving the overall situation of Chinese-style modernization. Aiwei Technology's holding of a centralized reception event for institutional investors is also a response to the 'Eight Measures for Sci-Tech Innovation'. By conducting exchanges involving private equity funds, industrial funds, and industry experts, it can bring many suggestions from the capital market to listed companies on the Sci-Tech Innovation Board, helping companies strengthen corporate governance, optimize operating strategies, and even discover opportunities for industrial investment and development, further promoting the development of high-quality productivity.

Industry-leading automated microscopy technology, significant performance growth trend

Data shows that Aiwei Technology is a pioneer and leader in automated microscopy technology in China. By applying "artificial intelligence + machine vision technology + big data" to the morphological testing of clinical specimens in medical and health institutions, Aiwei Technology has filled the technical gap in this field both internationally and domestically, promoting the industry's development from manual microscopy to automated microscopy.

Currently, in the field of automated microscopy, Aiwei Technology's product line has expanded from initial urine testing to multiple testing areas such as feces, gynecology, body fluids, and blood. At the same time, the company continues to deepen the clinical application of "artificial intelligence" and "machine vision technology," and its leading advantage in key core technologies continues to be consolidated.

Data shows that Aiwei Technology has led or participated in the development of 5 national industry standards, 2 local standards, and 2 group standards.

To date, the company's medical testing instruments have accumulated more than 15,000 sets of installations in China and have accumulated terminal installations in over 6,000 hospitals nationwide. Among them, the company's AVE-76 series, AVE-56 series, AVE-32 series, and other leading products for urine testing, stool testing, and reproductive tract secretion testing have been widely recognized by customers and are in a leading market position.

While achieving market leadership in instruments, Aiwei Technology actively develops supporting reagents and consumables products, ensuring testing accuracy while also opening up diversified sales sources for the company, forming a virtuous cycle of instrument promotion driving the sales of supporting reagents and consumables, laying a solid foundation for the company's continued performance growth.

Financial reports show that Aiwei Technology's 2023 revenue exceeded 200 million yuan, a year-on-year increase of 1.79%; net profit attributable to the parent company reached 21.5338 million yuan, a year-on-year increase of 19.81%; and non-net profit reached 12.4809 million yuan, a year-on-year increase of 98.98%.

In the first quarter of this year, the company's operating performance continued its growth trend, achieving revenue of 46.8138 million yuan, a year-on-year increase of 14.46%; and net profit attributable to the parent company of 5.0718 million yuan, a significant year-on-year increase of 136.42%.

Breakthroughs in multiple business areas expand growth space

In its more than 20 years of development, Aiwei Technology has always adhered to the core strategy of "innovation-driven development." As a pioneer and leader in automated microscopy technology both internationally and domestically, the company has been committed to automating microscopic morphological testing in medical testing since its establishment. This leading advantage in key common technologies is the company's core competitiveness. Improving and developing key core technologies, expanding product application areas, and maintaining a leading position in this niche market are essential for the company's survival. Based on this core technology, the company's product line has expanded from initial urine testing to areas such as feces, gynecology, body fluids, and blood testing. The company's new generation of urine modular analysis pipeline products, "1+2" and "2+4," and fully automated blood analysis pipeline products are in a leading market position with good market prospects and are expected to become new growth points for the company.

It is understood that another key development strategy direction for the company is the primary and civilian medical markets. On the one hand, targeting the characteristics of small scale, small sample size, and low automation requirements of primary medical and health institutions, the company has developed small, multi-functional instrument products to meet the clinical testing needs of primary medical and health institutions; on the other hand, targeting the civilian medical market, such as chronic disease management, health monitoring, and home self-testing, the company has developed dozens of lightweight POCT/iPOCT products in areas such as women's health, scientific pregnancy, childhood diarrhea, early tumor screening, gastrointestinal diseases, urinary system diseases, diabetes, and health testing. With the launch and market expansion of primary and civilian product lines, it is expected to become an important business growth point for the company in the future.

In addition, increasing efforts to expand overseas markets and increase international business revenue is also an important focus of the company's future development. (CIS)